SCHEMBL6450880

SCHEMBL6450880

[CH2]C(CC(=O)c1occ2ccccc12)Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.37
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
CYP1A2 P05177 1/20 0.36
CPA1 P15085 3/20 0.36
CPA3 P15088 2/20 0.36
CPB1 P15086 1/20 0.36
CPB2 Q96IY4 1/20 0.36
ACP3 P15309 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALPI P09923 1/20 0.34
PKM P14618 1/20 0.34
PTGS1 P23219 1/20 0.34
XIAP P98170 1/20 0.34
SLC7A5 Q01650 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MDM2 Q00987 1/20 0.33
CAPN1 P07384 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6447072 0.84 CAPN1 (0.37) MIFPPARGPPARACYP1A2CPA1
SCHEMBL10389827 0.84 CPA1 (0.53) CYP1A2CPA1CPA3CPB1CPB2
SCHEMBL7320860 0.84 CPA1 (0.53) CYP1A2CPA1CPA3CPB1CPB2
SCHEMBL10389853 0.73 NPC1 (0.53) CYP1A2TDP1
SCHEMBL11217485 0.72 NR4A2 (0.47) CYP1A2MEN1KMT2AHSD17B10KDM4E
SCHEMBL27272020 0.71 KMT2A (0.38) CYP1A2MEN1KMT2ANPSR1HSD17B10
SCHEMBL9667079 0.71 PTPN1 (0.51) CYP1A2MEN1KMT2AHSD17B10KDM4E
SCHEMBL547449 0.70 KDM4E (0.45) CYP1A2MEN1KMT2AHSD17B10KDM4E
SCHEMBL15524979 0.70 CPA3 (0.60) MIFCYP1A2CPA1CPA3CPB1
Hydrochloric Acid SCHEMBL11395268 0.69 LDHA (0.44) CYP1A2MEN1KMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
EP-1392315-A1 METHODS OF TREATING ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-03-03 EP disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
CN-1054598-C Pharmacologically active hydrazine derivatives and processes for preparation thereof NORVATIS CO (CH) 2000-07-19 CN disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP disclosed
CN-1068333-A Has hydrazine analog derivative of pharmacologically active and preparation method thereof CIBA GEIGY AG (CH) 1993-01-27 CN disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 MIF 3796/4885PPARG 2738/4885PPARA 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.